Renal Data: Switch Subset


DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

Switching to DESCOVY FOR PrEP resulted in increased eGFR vs TRUVADA®1,2

The long-term clinical significance of changes in eGFR is not known.1

Bone Data

eGFRCG=estimated glomerular filtration rate (Cockcroft-Gault); NSAIDs=nonsteroidal anti-inflammatory drugs; Q1, Q3=first quartile, third quartile.